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Scoring systemAbstract Background: Despite the well-known negative prognostic value of the V600EBRAF
mutation in patients with metastatic colorectal cancer (mCRC), its outcome is quite heteroge-
neous, and the basis for this prognostic heterogeneity should be better defined.
Methods: Two large retrospective series of V600EBRAF-mutated mCRC from 22 institutions
served as an exploratory and validation set to develop a prognostic score. The model was
internally and externally validated.
Results: A total of 395 V600EBRAF-mutated mCRCs were included in the exploratory set. Per-
formance status, CA19.9, lactate dehydrogenase, neutrophil/lymphocyte ratio, grading and
liver, lung and nodal involvement emerged as independent prognostic factors for overall sur-
vival (OS). Two different scoring systems were built: a ‘complete’ score (0e16) including all
significant covariates and a ‘simplified’ score (0e9), based only on clinicopathological covari-
ates, and excluding laboratory values. Adopting the complete score, proportions of patients
with a low (0e4), intermediate (5e8) and high (9e16) score were 44.7%, 42.6% and 12.6%,
respectively. The median OS was 29.6, 15.5 (hazard ratio [HR] for intermediate vs low risk:
2.16, 95% confidence interval [CI]: 1.44e3.22, p < .001) and 6.6 months (HR for high vs
low risk: 4.72, 95% CI: 2.72e8.20, p < .001). Similar results were observed also after adjusting
for the type of first-line treatment and adopting the simplified score. The simplified prognostic
score derived from the exploratory set was then applied to the validation set for external
confirmation.
Conclusions: These scoring systems are based on easy-to-collect data and defined specific sub-
groups with relevant differences in their life expectancy. These tools could be useful in clinical
practice, would allow better stratification of patients in clinical trials and may be adopted for
proper adjustments in exploratory translational analyses.
ª 2019 Elsevier Ltd. All rights reserved.1. Background
Somatic alteration of the BRAF gene at the valine 600
residue (V600EBRAF ) accounts for >90% mutation of
BRAF-mutated cancers and triggers the constitutive
activation of the epidermal growth factor recep-
toremediated MAPK pathway [1]. V600EBRAF muta-
tion occurs in roughly 10% of metastatic colorectal
cancer (mCRC) and leads to a peculiar and well-
described phenotype [2]. V600EBRAF-mutated mCRCs
are associated with female sex, advanced age, right-sided
primary tumour location, peritoneal metastases andmismatch repair deficiency/microsatellite instability-
high [3e6]. Moreover, the V600EBRAF mutation is
unanimously considered a negative prognostic determi-
nant in mCRC. In fact, the median overall survival (OS)
for this molecular subgroup ranges from 10 to 20
months [7]. Nevertheless, an intragroup heterogeneity
consistently emerges from all published series with
about 10e20% of V600EBRAF-mutated cases surviving
more than 2 years since the diagnosis of metastatic
disease [8e12]. A pooled meta-analysis of 3 randomised
clinical trials included a total of 231 patients with
V600EBRAF-mutated mCRC and reported more than
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months [7]. Another real-world analysis from 503 pa-
tients showed similar results [13].
The basis of this prognostic heterogeneity is still un-
clear. From a clinical perspective, surgical resection of
metastases with a curative intent could be a major
reason for long-term survival differences in CRC series
[14], but the impact of metastasectomy in V600EBRAF-
mutated mCRC is minimal: these patients rarely have
limited and exclusive liver and/or lung involvement, and
at the same time, some studies reported even shorter OS
and relapse-free survival after lung [15] and liver resec-
tion [16,17] for V600EBRAF-mutated cases. From a mo-
lecular perspective, clear differences among V600EBRAF-
mutated CRC were recently described in gene expression
[18]. Two distinct subgroups of V600EBRAF-mutated
CRC were recently distinguished: one (named BM1)
exhibiting high KRAS/mammalian target of rapamycin/
AKT/4EBP1, EMK activation and immune
infiltration and the other (named BM2) presenting cell
cycle checkpoint dysregulation. In addition, a cell drug
screen indicated that these subtypes may have different
responses to specific drugs, including BRAF and MEK
inhibitors.
Power and robustness of exploratory analyses in the
subgroup of patients with V600EBRAF-mutated CRC are
usually limited owing to the low incidence of the mu-
tation. In the present multicentre study, we pooled a
large number of fully annotated cases, with the aim of
building reliable and simple prognostic scores, poten-
tially useful for better informing clinicians, researchers
and patients on actual disease aggressiveness and life
expectancies.2. Materials and methods
2.1. Study design and participants
Consecutive patients with V600EBRAF-mutated mCRC
referred to 14 oncology units between January 2005 and
December 2016 were gathered in an exploratory set. For
details on collected data, see Appendix 1.
For building the external validation set, 8 additional
centres joined the initiative, and data on consecutive
eligible patients were gathered according to a predefined
statistical hypothesis (see in the following section). The
study was approved by local ethics committees (Onco-
logic Institute of Veneto, code 2017/34).2.2. Statistical analysis
The primary end-point was to determine the presence of
an independent prognostic factor for OS among patients
with V600EBRAF mCRC. Details on formal definitions
of end-points are reported in Appendix 2. An internal
cross-validation procedure was applied, and the wholestudy population was split into a training sample (67%)
and a testing one (33%); this process was repeated 10
times, obtaining 10 training samples and 10 corre-
sponding testing samples [19]. Multivariate analysis was
performed on each training sample, and covariates with
an independent prognostic value were retained in the
final model and included in the scoring system. The logs
of median hazard ratios (HRs) obtained from the 10
Cox models were used to derive weighting factors of a
prognostic index. Coefficient estimates were ‘normal-
ised’ by dividing by the smallest one and rounding the
resulting ratios to the nearest integer value. The sample
size of the validation set was based on the following
assumption: to observe the same distribution of risk
categories and the same survival observed previously,
145 events were overall needed to validate prognostic
differences among categories with 80% power and an
alpha error of 0.05.3. Results
3.1. Study population
A total of 395 consecutive patients with V600EBRAF-
mutated mCRC were included in the exploratory set.
Detailed patients’ characteristics are listed in Table 1.
The median age was 65 years (range: 24e88), and the
male/female ratio was 1:1. Of 395 patients, 65% had
right-sided CRC, and 71% had a metastatic disease ab
initio; liver metastases occurred in 56% of cases, whereas
nodal and peritoneal metastases occurred in 36% and
33% of cases, respectively. The majority of patients
(88%) received a first-line systemic treatment that most
frequently included a fluoropyrimidine-based doublet
plus bevacizumab (36%), followed by 5-fluorouracile,
oxaliplatin and irinotecan triplet combination (FOL-
FOXIRI) plus bevacizumab (24%). One hundred eighty-
six (47%) patients enrolled in at least 1 clinical study
during the course of their disease.3.2. Survival analyses in the whole population
At a median follow-up of 33.9 months, 260 patients
died, and the median OS was 19.6 months.
In the univariate analysis, OS was significantly worse
for an Eastern Cooperative Oncology Group (ECOG)
performance status (PS) of 1 or 2 (compared with an
ECOG PS of 0, p < .0001, and p < .0001, respectively),
not having the primary tumour resected (p < .0001), G3-
G4 tumour grading (p < .0001), presence of liver me-
tastases (pZ .014), lung metastases (pZ .014) or nodal
metastases (pZ .002) and the number of metastatic sites
2 (p < .0001).
Concerning the baseline laboratory values, OS was
significantly shorter in case of CA19.9 > upper limit of
normal (p Z .005), lactate dehydrogenase (LDH) >300
Table 1
Patient characteristics.
Characteristics Total Z 395 No (%)
Sex Female 197 (50)
Male 198 (50)
Age Median (range) 65 (24e88)
Age (70-year cut-off) >70 123 (31)
70 272 (69)
Baseline ECOG PS 0 212 (63)
1 99 (30)
2 25 (7)
NA 59
Baseline CEA Normal 111 (36)
> ULN (5 ng/mL) 196 (64)
NA 88
Baseline CA19.9 Normal 136 (46)
> ULN (37 UI/L) 162 (54)
NA 97
Baseline platelets Normal 274 (92)
> ULN (450  109/L) 25 (8)
NA 96
Baseline LDH Normal 78 (31)
> ULN (M Z 225
U/L F Z 214 U/L)
175 (69)
NA 142
Baseline ALP Normal 185 (70)
> ULN (M Z 128
U/L F Z 141 U/L)
79 (30)
NA 131
Baseline HgB 11 g/dL 235 (76)
<11 g/dL 73 (24)
NA 87
Baseline WBC Normal 267 (87)
 ULN (11 000/ml) 39 (13)
NA 89
NLR 3 167 (58)
>3 123 (42)
NA 105
Baseline albumin 4 g/dL 94 (48)
<4 g/dl 103 (52)
NA 198
Kohne score Low 181 (58)
Intermediate 94 (30)
High 36 (12)
NA 84
Primary tumour
resected
Yes 317 (80)
No 78 (20)
Adjuvant
chemotherapy
Yes 116 (29)
No 279 (71)
Adjuvant oxaliplatin Yes 87 (22)
No 29 (78)
Primary tumour
location
Right 256 (65)
Left 86 (22)
Rectum 50 (13)
NA 3
Mucinous histology Yes 78 (22)
No 280 (78)
NA 37
Lymphovascular
invasion
Yes 203 (79)
No 55 (21)
NA 137
Grading G1-G2 125 (39)
G3-G4 197 (61)
Table 1 (continued )
Characteristics Total Z 395 No (%)
NA 73
Presentation of
metastases
Synchronous 279 (71)
Metachronous 116 (29)
Sites of metastases at
diagnosis
Liver 223 (56)
Lung 73 (18)
Distant nodes 143 (36)
Peritoneum 132 (33)
Local relapse 11 (3)
Other 53 (1)
No. of metastatic
sites
1 226 (57)
2 169 (43)
ECOG, Eastern Cooperative Oncology Group; PS, performance status;
LDH, lactate dehydrogenase; ULN, upper limit of normal; CEA, car-
cinoembryonic antigen; NLR, neutrophils to lymphocytes ratio; WBC,
white blood cells; HgB, haemoglobin; ALP, alkalyne phosphatase.
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UI (pZ .010), haemoglobin <11 g/dL (pZ .044), white
blood cells (WBC)  11 000/ml (p Z .004), neutrophils
to lymphocytes ratio (NLR) >3 (p < .0001), albumin
<4 g/dL (p Z .041) and Ko¨hne risk score intermediate
(p Z .01) or high (p < .0001). Detailed HR and 95%
confidence interval (CI) are available in Table 2.
3.3. Multivariable analyses and the prognostic score
In the multivariable OS model, ECOG PS (1 vs 0; 2e3
vs 0), CA19.9 (high vs normal), LDH (300 vs low),
NLR (>3 vs  3), tumour grading (3e4 vs 1e2), liver
metastases (yes vs no), lung metastases (yes vs no) and
nodal metastases (yes vs no) retained their prognostic
impact in terms of OS. For each covariate retained in
the model, median values and interquartile ranges of the
10 estimates of HR are reported. Two different scoring
systems were built: a ‘complete’ score (0e16) including
all 8 significant covariates and a ‘simplified’ score (0e9),
selecting 5 significant covariates, excluding laboratory
values (see Table 3).
In the ‘complete’ score, three different risk categories
were defined: low (0e4), intermediate (5e8) and high
(9). The proportion of patients assigned to the 3 cat-
egories was 44.8%, 42.6% and 12.6%, respectively
(Supplementary Fig. 1). In the 10 testing samples, the
median OS estimates were 26.2 months (interquartile
range [IQR]: 23.0e30.9) for low the score, 15.7 months
(IQR: 14.6e18.7) for the intermediate score and 6.1
months (IQR: 3.8e7.4) for the high score.
Similarly, in the ‘simplified’ score, three different risk
categories were defined: low (0e2), intermediate (3e4)
and high (5). The proportion of patients assigned to
the 3 categories was 44.7%, 37.2% and 18.1%, respec-
tively (Supplementary Fig. 2). In the 10 testing samples,
the median OS estimates were 26.3 months (IQR:
24.7e29.8) for the low score, 15.9 months (IQR:
Table 2
Univariate analyses.
Characteristics Median OS (months) Overall survival
HR 95% CI p
Sex Male 19.6 1 e e
Female 19.3 1.00 0.79e1.29 0.972
Age 70 20.0 1 e -
>70 17.1 1.28 0.97e1.67 0.079
ECOG PS 0 23.6 1 e e
1 12.6 1.76 1.31e2.35 < 0.0001
2 2.9 5.25 3.28e8.41 < 0.0001
Baseline CEA Normal 19.8 1 e e
> ULN 17.1 1.22 0.91e1.64 0.192
Baseline CEA
>200 ng/mL No 18.8 1 e -
Yes 11.4 1.61 1.06e2.43 0.025
Baseline CA19.9 Normal 21.4 1 e -
> ULN 15.1 1.51 1.13e2.03 0.005
Baseline platelets Normal 18.2 1 e -
> ULN (450 < 109/L) 10.8 1.25 0.76e2.06 0.386
Baseline platelets
400 109/L No 18.8 1 e -
Yes 12.0 1.30 0.89e1.90 0.168
Baseline LDH Normal 26.0 1 e e
> ULN (M Z 225 U/L F Z 214 U/L) 16.0 1.55 1.07e2.24 0.019
Baseline LDH
300 U/L No 26.6 1 e e
Yes 14.2 1.93 1.42e2.64 < 0.0001
Baseline ALP Normal 21.0 1 e e
> ULN (M Z 128 U/L F Z 141 U/L) 14.4 1.41 1.03e1.93 0.031
Baseline ALP
300 U/L No 19.8 1 e e
Yes 11.7 1.73 1.14e2.61 0.010
Baseline HgB 11 g/dL 18.8 1 e e
<11 g/dl 14.5 1.38 1.01e1.89 0.044
Baseline WBC Normal 19.6 1 e e
 ULN (11 000/ml) 10.8 1.78 1.20e2.63 0.004
NLR 3 25.0 1 e -
>3 12.7 2.01 1.50e2.68 < 0.0001
Baseline albumin 4 g/dL 22.5 1 e e
<4 g/dl 14.5 1.42 1.01e1.98 0.041
Kohne score Low 22.8 1 e e
Intermediate 15.4 1.51 1.10e2.07 0.01
High 5.1 3.74 2.51e5.59 < 0.0001
Primary tumour resection Yes 23.0 1 e e
No 11.3 2.56 1.89-3.41 < 0.0001
Primary tumour location Right 19.6 1 e e
Left 21.4 0.81 0.60-1.11 0.189
Rectum 16.3 0.96 0.68-1.36 0.822
Primary tumour location Right 19.6 1 e -
Left rectum 21.4 0.87 0.67-1.13 0.290
Mucinous histology No 20.5 1 e e
Yes 19.6 0.97 0.71-1.34 0.860
Lymphovascular invasion No 26.7 1 e -
Yes 18.4 1.35 0.93-1.96 0.114
Grading G1-2 27.4 1 e -
G3-4 14.7 1.98 1.48-2.65 < 0.0001
Presentation of metastasis Metachronous 23.8 1 e e
Synchronous 16.0 1.18 0.90-1.54 0.224
Liver metastasis at diagnosis No 21.8 1 e e
Yes 15.9 1.37 1.07-1.76 0.014
Lung metastasis at diagnosis No 22.0 1 e e
Yes 14.0 1.46 1.08-1.97 0.014
Nodal metastasis at diagnosis No 23.0 1 e e
Yes 14.4 1.52 1.17-1.97 0.002
(continued on next page)
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Table 2 (continued )
Characteristics Median OS (months) Overall survival
HR 95% CI p
Peritoneal metastasis at diagnosis No 21.4 1 e e
Yes 16.0 1.21 0.94-1.57 0.14
No. of metastatic sites 1 25.8 1 e e
2 14.0 1.95 1.52-2.50 < 0.0001
MSI status MSS 22.4 1 e e
MSI-H 24.3 0.87 0.57-1.34 0.532
P-values below 0.05 in bold.
MSI-H, microsatellite instability-high; MSI, microsatellite instability; HR, hazard ratio; CI, confidence interval; OS, overall survival; ECOG,
Eastern Cooperative Oncology Group; PS, performance status; ULN, ULN, upper limit of normal; LDH, lactate dehydrogenase; ALP, alkalyne
phosphatase; WBC, white blood cells; NLR, neutrophils to lymphocytes ratio; CEA, carcinoembryonic antigen; HgB, haemoglobin; MSS, mi-
crosatellite stable.
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(IQR: 5.5e8.4) for the high score.3.4. Outcome for different risk score categories in the
whole study population
The OS results for the ‘complete’ and ‘simplified’ prog-
nostic classifiers in the whole study population are re-
ported in Fig. 1.
According to the ‘complete’ prognostic score system,
the median OS for patients included in the high-risk
group was 6.6 months (95% CI: 5.1e8.0; HR high vs low
risk: 4.72; 95% CI: 2.72e8.20, p < .001); for the inter-
mediate-risk group, it was 15.5 months (95% CI:
10.2e20.8; HR intermediate vs low risk: 2.16; 95% CI:
1.44e3.22, p < .001) and for the low-risk group, it was
29.6 months (95% CI: 20.4e38.9) (Fig. 1A).
Adopting the ‘simplified’ prognostic score system, the
3 different risk score categories maintained theirTable 3
Multivariate models and scoring systems for the ‘complete score’ and ‘sim
Complete score
Characteristics Median HR IQ range
ECOG PS 1 vs 0 2.62 2.22e3.24
ECOG PS 2-3 vs 0 7.26 3.68e9.36
CA19.9 High vs normal 1.61 1.14e2.26
LDH 300 vs low 1.86 1.66e2.33
NLR >3 vs  3 1.54 1.22e1.97
Grading 3-4 vs 1-2 1.78 1.46e2.16
Liver Yes vs no 2.22 2.08e2.50
Lung Yes vs no 3.64 2.89e4.50
Nodes Yes vs no 2.73 1.79e3.61
Simplified score
Characteristic Median HR IQ range L
ECOG PS 1 vs 0 2.62 2.22e3.24 0
ECOG PS 2-3 vs 0 7.26 3.68e9.36 0
Grading 3-4 vs 1-2 1.78 1.46e2.16 0
Liver Yes vs no 2.22 2.08e2.50 0
Lung Yes vs no 3.64 2.89e4.50 0
Nodes Yes vs no 2.73 1.79e3.61 0
HR, hazard ratio; IQ, interquartile; ECOG, Eastern Cooperative Oncolog
neutrophils to lymphocytes ratio.prognostic relevance with a median OS of 7.0 (95% CI:
5.1e9.0), 15.9 (95% CI: 11.0e20.7) and 26.7 (95% CI:
23.5e29.9) months for high, intermediate and low risk,
respectively (HR intermediate vs low risk: 1.71; 95% CI:
1.22e2.41, pZ .002; HR high vs low risk: 4.62; 95% CI:
3.11e6.85, p < .001) (Fig. 1B).
Similarly, according to either the ‘complete’ or
‘simplified’ score system, median progression-free sur-
vival (PFS) was significantly shorter for intermediate-
and high-risk score subgroups than the low-risk one
(Supplementary Fig. 3). Details on PFS results are
available in Appendix 3.3.5. OS adjusted for intensity of first-line systemic
treatment
The impact on survival results of administered treatments
and their relation to the prognostic classifiers were further
explored. To that purpose, first-line therapies wereplified score’.
Log (median HR) Normalised log (HR) Rounded score
0.419 2.24 2
0.861 4.61 5
0.205 1.10 1
0.270 1.44 1
0.187 1.0 1
0.250 1.34 1
0.347 1.86 2
0.561 3.00 3
0.436 2.33 2
og (median HR) Normalized log (HR) Rounded score
.419 1.67 2
.861 3.44 3
.250 1.0 1
.347 1.39 1
.561 2.24 2
.436 1.74 2
y Group; PS, performance status; LDH, lactate dehydrogenase; NLR,
Fig. 1. Overall survival (OS) according to complete risk score categories (A) and simplified risk score categories (B). (A) Complete risk
score e OS, red line: high risk (NZ 24), median OSZ 6.6 months (95% CI: 5.1e8.0)., green line: intermediate risk (NZ 81), median OS
Z 15.5 months (95% CI: 10.2e20.8)., blue line: low risk (NZ 85), median OSZ 29.6 months (95% CI: 20.4e38.9), intermediate risk vs
low risk, HR Z 2.16 (95% CI: 1.44e3.22), p < .001, high risk vs low risk, HR Z 4.72 (95% CI: 2.72e8.20), p < .001 (B) Simplified risk
score e OS, red line: high risk (NZ 51), median OSZ 7.0 months (95% CI: 5.1e9.0), green line: intermediate risk (NZ 105), median OS
Z 15.9 months (95% CI: 11.0e20.7), blue line: low risk (NZ 126), median OSZ 26.7 months (95% CI: 23.5e29.9), intermediate risk vs
low risk, HRZ 1.71 (95% CI: 1.22e2.41), pZ .002, high risk vs low risk, HRZ 4.62 (95% CI: 3.11e6.85), p < .001. (For interpretation
of the references to colour in this figure legend, the reader is referred to the Web version of this article.) CI, confidence interval; HR,
hazard ratio.
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treatment defined on the basis of the number of concom-
itant chemotherapy drugs (1 vs 2- vs 3-drug regimens).
Twenty-eight patients received an anti-BRAF experi-
mental treatment (nZ 7) or no treatment (nZ 21).A total
of 16, 85 and 61 patients were treated with single-agent
chemotherapy, a doublet or a triplet as backbone
chemotherapy, respectively (Supplementary Table 1).
In a multivariable analysis including the type of
treatment and the risk category, OS differed significantly
between patients who underwent to one- (HR: 0.27; 95%
CI: 0.11e0.67, p Z .005), two- (HR 0.16; 95% CI,
0.08e0.34, p < .001) or three-drug regimen (HR 0.15;
95% CI: 0.07e0.33, p < .001) compared with those
untreated.
Notably, the risk category retained an independent
prognostic value also in this model adjusted by type of
treatment: HR for intermediate vs low risk 2.42 (95%
CI: 1.59e3.70, p < .001) and HR for high vs low risk
4.69 (95% CI: 2.66e8.29, p < .001).
Similar results were observed when ‘simplified score’
performance was adjusted by treatment.
3.6. External validation
Data from 252 consecutive patients with V600EBRAF-
mutated mCRC were prospectively gathered in a vali-
dation set. Adopting the simplified score, the proportion
of patients assigned to low-, intermediate- and high-risk
score categories was 38.5%, 31.0% and 30.5%, respec-
tively. At the time of analyses, 150 death events occurred.
The median OS for patients included in the high-risk
group was 8.9months (HR high vs low risk: 3.39; 95%CI:3.10e7.20, p< .0001), in the intermediate-risk group was
23.7 months (HR high vs intermediate risk: 2.70; 95% CI:
2.04e4.60, pZ<0.0001) and in the low-risk group was
26.1 months (HR intermediate vs low risk: 1.01; 95% CI:
0.66e1.53, p Z .98). A specific web-based application
(named ‘BRAF BeCool’) for easy calculation of the
simplified score was developed and is available for
download in iOS 8.0 and Android 5.0 or later.
4. Discussion
The present work is based on one of the largest series of
V600EBRAF-mutated mCRCs. Its rationale came from
the need for a specific survival classifier for these pa-
tients, generally marked as a subgroup with extremely
poor prognosis. Indeed, data from previous publications
suggest a high degree of heterogeneity in the outcome
with a not-negligible proportion of long-term survivors
[7]. However, these analyses were limited in the sample
size, included different stages, and were mainly focussed
on describing differences between BRAF-mutated and
wild-type patients [7,13]. Most of the information
available in the literature is derived from post hoc an-
alyses of clinical studies [9,10,20], whose inclusion
criteria clearly restrict eligibility to a selected subgroup
of V600EBRAF-mutated patients, thus introducing a
relevant bias when transferring these results to the real
world. In our work, subjects enrolled in clinical trials
and those who were treated outside clinical trials were
balanced, thus providing a data set depicting a real-
world scenario.
The major and clinically relevant finding is that pa-
tients with V600EBRAF-mutated mCRC might be
F. Loupakis et al. / European Journal of Cancer 118 (2019) 121e130128classified into 3 distinct prognostic subgroups (i.e. low-,
intermediate- and high-risk), by means of simple and
easy-to-use clinicopathological classifiers. Thus, the
present scoring systems may have potential implications
at 3 different levels: (i) clinical, (ii) methodological and
(iii) translational.
From a clinical perspective, the prognostic classifier
may affect specific crucial points of clinical decision-
making. Given the retrospective and observational na-
ture of our analysis, we cannot draw specific conclusions
regarding the relative efficacy of more versus less
intensive treatments. Nevertheless, the presence of
extremely bad prognostic features may suggest some
caution when considering specific strategies such as
resection of metastases, in a careful evaluation of risk/
benefit balance. To this extent, we should acknowledge
that available data on secondary resection of metastases
and specific outcome parameters (such as resection
margins) were limited in our data sets and no specific
considerations could be drawn. On the other hand, life
expectancy for the good-prognosis subgroup of mutated
cases is not much lower than unselected patients with
wild-type tumour. Therefore, those patients should not
be stigmatised simply as a group with low chance of
survival based on BRAF mutational status because this
may influence clinicians’ attitude towards specific ther-
apeutic choices. Furthermore, an informative discussion
on prognosis was recently demonstrated to strengthen
the therapeutic alliance between patients and oncolo-
gists, thus underlying the clinical relevance of a robust
prognostic score [21].
Other than a prognostic marker, the V600EBRAF
mutation is a potential key molecular target [22e26].
Several studies are currently testing BRAF inhibitors in
mCRC. From a methodological perspective, the prog-
nostic score could refine the criteria for the stratification
of patients in those trials. This would be much more
appropriate than adopting the same prognosticators
derived from studies conducted in unselected mCRC. As
an example, the primary tumour location has recently
gained consideration a reliable prognostic factor in wild-
type mCRCs [27], thus being proposed as a stratification
factor for design of new trials. In our series of
V600EBRAF-mutated patients, the primary tumour
location was not prognostic. In fact, most of the data
showing a significantly worse outcome for right-sided
primary tumours were not powered for looking specif-
ically at the BRAF-mutated subgroup [28,29]. At the
same time, this observation should be considered as
preliminary and hypothesis generating.
Finally, looking at the potential utility of our data
from a translational perspective, it should be considered
how often preliminary analyses aiming at the discovery
of new useful biomarkers are hampered by limited
clinical data. A better knowledge of the main specific
prognostic factors in selected subgroups would allow
reliable multivariate models to be built, including riskcategories as covariates, in future translational studies.
Similar considerations and specific proposals were made
years ago for molecularly unselected patients, and those
approaches improved clinical trial quality and robust-
ness of data [30].
The retrospective part of our work has usual intrinsic
limitations. First, owing to the long time frame set for
retrieving such high numbers of V600EBRAF-mutated
patients, our analysis retained an intrinsic time-lag bias.
Second, we tested the microsatellite instability status in
less than half of the patients; however, this will be
explored in ad hoc translational studies. Third, despite
adjusting survival analysis for the possible impact of
treatment, such adjustment was limited to a simplified
categorisation based on the intensity of the chemo-
therapy backbone (1 vs 2 vs 3 drugs); further subgroup
analyses would have been impaired by very low power.
Adjustments were made only according to first-line
treatment data, but it should be noted that the impact
on OS of second and later lines in V600EBRAF-mutated
patients is extremely limited [7]. It should be noted that
these limitations are unavoidable in retrospective ana-
lyses, which on the other hand have the advantage of
describing the real-world experience.
From a methodological point of view, the prognostic
model is at risk of overfitting bias [31]. We tried to reduce
this bias by adopting an internal cross-validation pro-
cedure, working on training and validation samples
randomly selected among the study population. Howev-
er, this limitation was overcome by the prospective vali-
dation of the simplified score in an external independent
series of consecutive patients. The distribution of patients
in the 3 categories reproduced the initial retrospective
data with a slightly higher rate of assignment to the high-
risk group. It could be speculated that the prospective
enrolment with absolutely no patient exclusion may have
influenced that, given that the loss of bad prognosis pa-
tients could be more frequent in historical databases.
Relatively short follow-up may have influenced the lack
of statistical significance in differences between interme-
diate- and low-risk categories.5. Conclusion
Robust clinical prognostic classifiers for patients with
V600EBRAF-mutated mCRC are developed and vali-
dated. Both prognostic scores allow discrimination of 3
subgroups with significantly different outcomes, con-
firming the hypothesis of intragroup heterogeneity
among V600EBRAF-mutated mCRC. These easy-to-
collect data might be clinically useful and may guide
stratification choices in future clinical trials and
strengthen translational studies. The BeCool platform is
currently running a translational research programme
focussed on exploring how molecular factors (such as
BM1/BM2 and consensus molecular subtypes (CMS)
F. Loupakis et al. / European Journal of Cancer 118 (2019) 121e130 129categorisation systems) recently proposed as possible
basis for V600EBRAF-mutated mCRC heterogeneity
would fit in innovative prognostic models.
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